Drug Trial Radar · NCT00750880
An Exploratory Study of Tocilizumab in Patients With Active Rheumatoid Arthritis (RA) and an Inadequate Response to Current Non-Biologic DMARDs and/or Anti-TNF Therapy.
Last checked: Nov 20, 2026Latest source record: Jul 22, 2015 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,681
Actual
Start
Sep 2008
Primary completion
Jul 2011
Study completion Jul 2011
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- Sep 11, 2008
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This open-label, single arm study will investigate the safety, tolerability and efficacy of tocilizumab monotherapy, or combination therapy with non-biologic disease modifying antirheumatic drugs (DMARDs), in patients with severe active RA. Patients will receive tocilizumab 8mg/kg iv as a 60 minute infusion every 4 weeks for a total of 6 infusions. The anticipated time on study treatment is 3-12 months, and the target sample size is \>500 individuals.
Conditions
- Rheumatoid Arthritis
Interventions
tocilizumab [RoActemra/Actemra]Drug
8mg/kg iv (60 minute infusion)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With Adverse Events (AEs): Overall SummaryTime frame: Weeks 4, 8, 12, 16, 20, and 24
Locations
282 sites in 25 countries. Site status is shown where the registry gives one.
Site not named
Canberra, Australian Capital Territory, Australia
Site not named
Coffs Harbour, New South Wales, Australia
Site not named
Kogarah, New South Wales, Australia
Site not named
Parramatta Park, New South Wales, Australia
Site not named
Adelaide, South Australia, Australia
Site not named
Fitzroy, Victoria, Australia
Site not named
Geelong, Victoria, Australia
Site not named
Melbourne, Victoria, Australia
Site not named
Graz, Austria
Site not named
Graz-Eggenberg, Austria
Site not named
Innsbruck, Austria
Site not named
Linz, Austria
Site not named
Salzburg, Austria
Site not named
Stockerau, Austria
Site not named
Vienna, Austria
Site not named
Vienna, Austria
Site not named
Vienna, Austria
Site not named
Aalst, Belgium
Site not named
Brussels, Belgium
Site not named
Brussels, Belgium
Site not named
Brussels, Belgium
Site not named
Brussels, Belgium
Site not named
Edegem, Belgium
Site not named
Ghent, Belgium
Site not named
Hasselt, Belgium
Site not named
Heusy, Belgium
Site not named
Leuven, Belgium
Site not named
Liège, Belgium
Site not named
Merksem, Belgium
Site not named
Montignies S/ Sambre, Belgium
Site not named
Westmalle, Belgium
Site not named
Edmonton, Alberta, Canada
Site not named
Lethbridge, Alberta, Canada
Site not named
Kelowna, British Columbia, Canada
Site not named
Nanaimo, British Columbia, Canada
Site not named
Vancouver, British Columbia, Canada
Site not named
Vancouver, British Columbia, Canada
Site not named
Quispamsis, New Brunswick, Canada
Site not named
St. John's, Newfoundland and Labrador, Canada
Site not named
Hamilton, Ontario, Canada
Showing 40 of 282 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.